Efficacy and safety of alemtuzumab in patients with relapsing-remitting MS who relapsed on prior therapy: four-year follow-up of the CARE-MS II study

被引：0
|
作者：
Hartung, H-P [1 ,2 ]
Arnold, D. L. [3 ]
Cohen, J. A. [4 ,5 ]
Coles, A. J. [6 ]
Fox, E. J. [7 ]
Havrdova, E. [8 ]
Selmaj, K. W. [9 ]
Margolin, D. H. [10 ]
Palmer, J. [10 ]
Oyuela, P. [10 ]
Panzara, M. A. [10 ]
Compston, D. A. S. [11 ]
机构：
[1] Univ Dusseldorf, Dept Neurol, Dusseldorf, Germany
[2] Univ Dusseldorf, Ctr Neuropsychiat, Dusseldorf, Germany
[3] McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada
[4] Cleveland Clin, Mellen Ctr, Cleveland, OH 44106 USA
[5] Cleveland Clin, Dept Biomed Engn, Cleveland, OH 44106 USA
[6] Univ Cambridge, Addenbrookes Hosp, Cambridge CB2 2QQ, England
[7] Univ Texas Med Branch, Round Rock, TX USA
[8] Charles Univ Prague, Dept Neurol, Sch Med 1, Prague, Czech Republic
[9] Med Univ Lodz, Dept Neurol, Lodz, Poland
[10] Genzyme, Cambridge, MA USA
[11] Univ Cambridge, Dept Clin Neurosci, Cambridge, England
来源：
MULTIPLE SCLEROSIS JOURNAL | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P043
引用
收藏
页码：85 / 86
页数：2
相关论文
共 50 条
  • [41] Natalizumab results in sustained freedom from disease activity in highly active relapsing-remitting MS patients: a four-year follow-up
    Kelly, S. B.
    Duggan, M.
    Buckley, L.
    Kinsella, K.
    Hutchinson, M.
    Tubridy, N.
    McGuigan, C.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 225 - 225
  • [42] Alemtuzumab Improves Clinical Outcomes Over 4 Years in Patients With Relapsing-Remitting Multiple Sclerosis Who Discontinued SC IFNB-1a: CARE-MS II Extension Study 4-Year Follow-up
    Boyko, Alexey N.
    Barnett, Michael
    Brassat, David
    Dive, Dominique
    Hupperts, Raymond M. M.
    Lycke, Jan
    Montalban, Xavier
    Sharrack, Basil
    Wray, Sibyl
    Margolin, David H.
    Thangavelu, Karthinathan
    Chirieac, Madalina
    Wiendl, Heinz
    NEUROLOGY, 2017, 88
  • [43] Alemtuzumab has a durable effect on disability improvement in treatment-naive patients with relapsing-remitting multiple sclerosis: a 4-year follow-up of CARE-MS I
    Fernandez Fernandez, O.
    Hartung, H-P
    LaGanke, C.
    Margolin, D. H.
    Kasten, L.
    Moreau, T.
    Giovannoni, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 824 - 824
  • [44] Alemtuzumab improves MRI outcomes in treatment-naive active relapsing-remitting multiple sclerosis patients: three-year follow-up from CARE-MS I
    Arnold, D. L.
    Barkhof, F.
    Cohen, J. A.
    Fox, E. J.
    Selmaj, K. W.
    Margolin, D. H.
    Palmer, J.
    Fisher, E.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 41 - 41
  • [45] Lymphocyte counts and infection risk among relapsing-remitting multiple sclerosis patients treated with alemtuzumab (CARE-MS II)
    Havrdova, E.
    Arnold, D. L.
    Cohen, J. A.
    Coles, A. J.
    Confavreux, C.
    Fox, E. J.
    Hartung, H. -P.
    Selmaj, K. W.
    Weiner, H. L.
    Miller, T.
    Twyman, C. L.
    Lake, S. L.
    Margolin, D. H.
    Panzara, M. A.
    Compston, D. A. S.
    JOURNAL OF NEUROLOGY, 2013, 260 : S120 - S120
  • [46] Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies
    Comi, Giancarlo
    Alroughani, Raed
    Boster, Aaron L.
    Bass, Ann D.
    Berkovich, Regina
    Fernandez, Oscar
    Kim, Ho Jin
    Limmroth, Volker
    Lycke, Jan
    Macdonell, Richard A. L.
    Sharrack, Basil
    Singer, Barry A.
    Vermersch, Patrick
    Wiendl, Heinz
    Ziemssen, Tjalf
    Jacobs, Alan
    Daizadeh, Nadia
    Rodriguez, Claudio E.
    Traboulsee, Anthony
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (14) : 1866 - 1876
  • [47] Relapse Outcomes with Alemtuzumab vs IFNB-1a in Active Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II)
    Twyman, Cary
    Montalban, Xavier
    Arnold, Douglas
    Cohen, Jeffrey
    Coles, Alasdair
    Confavreux, Christian
    Fox, Edward
    Hartung, Hans
    Havrdova, Eva
    Selmaj, Krzysztof
    Weiner, Howard
    Miller, Tamara
    Lake, Stephen
    Margolin, David
    Panzara, Michael
    Compston, Alastair
    NEUROLOGY, 2013, 80
  • [48] 7-Year Outcomes in MS Patients of African Descent Treated With Alemtuzumab: Follow-up of CARE-MS I and II (TOPAZ study)
    Williams, Mitzi
    Amezcua, Lilyana
    Berkovich, Regina
    Chinea, Angel
    Edwards, Keith
    Steingo, Brian
    Walker, Aljoeson
    Jacobs, Alan
    Daizadeh, Nadia
    Okai, Annette
    NEUROLOGY, 2019, 92 (15)
  • [49] 7-year outcomes in MS patients of African descent treated with alemtuzumab: follow-up of CARE-MS I and II (TOPAZ Study)
    Williams, M.
    Amezcua, L.
    Berkovich, R.
    Chinea, A.
    Edwards, K.
    Goldman, M.
    Steingo, B.
    Walker, A.
    Jacobs, A.
    Daizadeh, N.
    Okai, A.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 489 - 490
  • [50] Alemtuzumab Provides Durable Efficacy Over 6 Years in Patients With Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy in the Absence of Continuous Treatment (CARE-MS II)
    Fox, Edward J.
    Brassat, David
    Alroughani, Raed
    Broadley, Simon
    Cohen, Jeffrey
    Hartung, Hans-Peter
    Havrdova, Eva
    Oreja-Guevara, Celia
    Selmaj, Krzysztof W.
    Singer, Barry
    Vermersch, Patrick
    Wray, Sibyl
    Margolin, David H.
    Thangavelu, Karthinathan
    Chirieac, Madalina C.
    Coles, Alasdair
    NEUROLOGY, 2017, 88
12345